Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Investing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Cash from Investing Activities for 8 consecutive years, with -$142.8 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 393.82% year-over-year to -$142.8 million; the TTM value through Mar 2026 reached -$712.5 million, down 2766.69%, while the annual FY2025 figure was -$521.1 million, 28.95% down from the prior year.
  • Cash from Investing Activities hit -$142.8 million in Q1 2026 for Kymera Therapeutics, up from -$394.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $81.8 million in Q2 2022 and bottomed at -$394.4 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$53.4 million, with a median of $19.0 million recorded in 2023.
  • Year-over-year, Cash from Investing Activities tumbled 1444.81% in 2024 and then skyrocketed 283.72% in 2025.
  • Kymera Therapeutics' Cash from Investing Activities stood at -$49.7 million in 2022, then surged by 138.16% to $19.0 million in 2023, then soared by 261.8% to $68.6 million in 2024, then plummeted by 675.19% to -$394.4 million in 2025, then skyrocketed by 63.78% to -$142.8 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$142.8 million, -$394.4 million, and -$235.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.